Black and Hispanic Americans seem to experience more symptoms and health problems related to long COVID—a lay term that captures an array of symptoms and health problems—than White people, but are not as likely to be diagnosed with the condition, according to new research funded by the National Institutes of Health. The findings from two different studies by NIH’s Researching COVID to Enhance Recovery (RECOVER) Initiative help better understand the complex symptoms and other issues associated with long COVID that millions have experienced.
“This new evidence suggests that there may be important differences in how long COVID manifests in different racial and ethnic groups,” said Mitchell S.V. Elkind, MD, professor of neurology and epidemiology, Columbia University, New York City, NY, and chief clinical science officer for the American Heart Association. “However, further research is needed to better understand the mechanisms for these differences in symptoms and access to care, and also if diagnostic codes assigned by clinicians may play a role.”
Studies showing disparity in COVID-19 symptoms in different races
In one analysis, published in the Journal of General Internal Medicine, researchers looked at the health records of 62,339 adults who received a positive COVID-19 test at one of five academic health centers in New York City, all between March 2020 and October 2021. They tracked the patients’ health for one to six months after the positive test and compared the findings to 247,881 adults who never had COVID-19.
Among 13,106 adults who had severe COVID-19 that required hospital care, the researchers found Black and Hispanic adults were disproportionately represented. Of those who had these severe cases, for example, one in four were Black adults, one in four were Hispanic adults, and one in seven were White adults.
In the months following infection, Black adults with severe disease were more likely than White adults to be diagnosed with diabetes and experience headaches, chest pain, and joint pain, but less likely to have sleep disorders, cognitive problems, or fatigue. Similarly, Hispanic adults who required hospital care were more likely than White adults to have headaches, shortness of breath, joint pain, and chest pain, but less likely to have sleep disorders, cognitive problems, or fatigue.
Similar patterns emerged among people with mild to moderate disease. Among patients who were not hospitalized, Black adults were more likely to have blood clots in their lungs, chest pain, joint pain, anemia, or malnourishment. Hispanic adults were more likely than White adults to have dementia, headaches, anemia, chest pain, and diabetes. Conversely, White adults were most likely to have conditions such as cognitive impairment (sometimes referred to as brain fog) and fatigue.
The researchers also found that in comparison to people who did not have COVID-19, those who did were more likely to experience conditions affecting their nervous system, respiratory function, and circulation, and more likely to feel fatigued or have joint pain.
“It’s not clear what's behind these symptom variations,” said Dhruv Khullar, MD, physician, assistant professor of health policy and economics at Weill Cornell Medicine, New York City, NY, and the first author of the paper. “We hope this work draws attention to possible differences across racial and ethnic groups, stimulates research into the potential mechanisms, and sparks discussion among patients, clinicians, and policymakers.”
In the second study, which was published in BMC Medicine, researchers analyzed data from the electronic health records of 33,782 adults and children who received a diagnosis of long COVID between October 2021 and May 2022 at one of 34 US medical centers. All had been given a diagnosis—post-COVID-19 condition, unspecified—the code for the condition first introduced in US healthcare systems in October 2021.
Key findings and patterns in the studies
In studying the profile of these patients and their symptoms, the researchers found multiple patterns. Among the more striking: most of the patients were White, female, non-Hispanic, and likely to live in areas with low poverty and greater access to healthcare.
Given what researchers already knew about the disproportionate impact of COVID-19 on people of color and economically disadvantaged populations, the findings stood out. Emily Pfaff, PhD, assistant professor in the Division of Endocrinology and Metabolism at the University of North Carolina, Chapel Hill, NC, and the first author of the paper, said the pattern suggested that not all patients who have long COVID are being diagnosed.
The reasons vary. In addition to long-documented health disparities based on race and other factors, women are more likely than men to seek healthcare, in general, and patients with the time and resources to access healthcare tend to be disproportionately represented in clinical data. “You can see all the different ways these diagnostic codes can provide insight, but they can also skew the whole story,” said Pfaff.
Still, she added, the insights help. She and her team found, for example, that most of the patients with long COVID had just mild to moderate, not severe, symptoms of acute infection. They also discovered that long-term symptoms could be grouped into common clusters—cardiopulmonary, neurological, gastrointestinal, and coexisting conditions—as well as by age.
Children and teens were more likely to experience gastrointestinal and upper respiratory problems, including stomach aches and coughing. Adults aged 21–45 years commonly experienced neurological problems, such as brain fog and fatigue. Adults ages 66 and older were more likely to have coexisting conditions, such as heart problems and diabetes, which the authors suspect are more likely present because of age than long COVID.
The authors of both papers said additional studies are needed to confirm and further categorize these trends.
“This research contributes to our understanding of symptom clusters in long COVID that may be differentiated by race, ethnicity, and influenced by social determinants of health,” said Gary H. Gibbons, MD, director of the National Heart, Lung, and Blood Institute, MD. “It also provides vital insights into the utility, as well as the constraints, of the diagnostic code now in use for long COVID.”
Both studies were funded by RECOVER (HL161847-01). The National Center for Advancing Translational Sciences provided additional support for the review published in BMC Medicine through the National COVID Cohort Collaborative (N3C) Data Enclave (U24TR002306).
- This press release was originally published on the National Institutes of Health website